{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:48:55Z","timestamp":1793065735974,"version":"4.5.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008527","name":"Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine","doi-asserted-by":"publisher","award":["P30 CA125123"],"award-info":[{"award-number":["P30 CA125123"]}],"id":[{"id":"10.13039\/100008527","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10 OD026804"],"award-info":[{"award-number":["S10 OD026804"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA214125"],"award-info":[{"award-number":["U01CA214125"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP170005"],"award-info":[{"award-number":["RP170005"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP210227"],"award-info":[{"award-number":["RP210227"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP220646"],"award-info":[{"award-number":["RP220646"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.xcrm.2025.102255","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T14:35:45Z","timestamp":1753972545000},"page":"102255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"6","author":[{"given":"Matthew V.","family":"Holt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchao","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meggie N.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B.","family":"Saltzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Anurag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan T.","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antrix","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom-Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacey E.","family":"Dobrolecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie F.","family":"Faucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Kremers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle D.","family":"Drinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia D.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Ittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehak Mehboob","family":"Khatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Malovannaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6379-2581","authenticated-orcid":false,"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102255_bib1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eururo.2005.04.005","article-title":"Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","volume":"48","year":"2005","journal-title":"Eur. Urol."},{"key":"10.1016\/j.xcrm.2025.102255_bib2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102255_bib3","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"Griffiths","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102255_bib4","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-20-2409","article-title":"A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)","volume":"27","author":"Flaig","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102255_bib5","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102255_bib6","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.xcrm.2025.102255_bib7","doi-asserted-by":"crossref","first-page":"LBA531","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA531","article-title":"AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation","volume":"42","author":"Ballman","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102255_bib8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.2023.41.6_suppl.438","article-title":"A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN)","volume":"41","author":"Geynisman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102255_bib9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102255_bib10","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102255_bib11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nature14034","article-title":"Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance","volume":"517","author":"Kurtova","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102255_bib12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102255_bib13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102255_bib14","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102255_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102255_bib16","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2025.102255_bib17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13046-023-02635-y","article-title":"Research progress on non-protein-targeted drugs for cancer therapy","volume":"42","author":"Zhang","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102255_bib18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102255_bib19","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102255_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102255_bib21","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102255_bib22","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1158\/2159-8290.CD-13-0219","article-title":"Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium","volume":"3","author":"Ellis","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102255_bib23","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41596-018-0006-9","article-title":"Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry","volume":"13","author":"Mertins","year":"2018","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2025.102255_bib24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/path.5420","article-title":"A streamlined mass spectrometry-based proteomics workflow for large-scale FFPE tissue analysis","volume":"251","author":"Coscia","year":"2020","journal-title":"J. Pathol."},{"key":"10.1016\/j.xcrm.2025.102255_bib25","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1158\/2159-8290.CD-22-0200","article-title":"Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer","volume":"12","author":"Anurag","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102255_bib26","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ccell.2023.06.009","article-title":"Proteogenomic data and resources for pan-cancer analysis","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102255_bib27","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1016\/j.cell.2023.07.004","article-title":"Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer","volume":"186","author":"Chowdhury","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102255_bib28","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.cell.2024.01.027","article-title":"Pan-cancer proteogenomics characterization of tumor immunity","volume":"187","author":"Petralia","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102255_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature18003","article-title":"Proteogenomics connects somatic mutations to signalling in breast cancer","volume":"534","author":"Mertins","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102255_bib30","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0090-4295(00)00523-9","article-title":"Gender differences in stage-adjusted bladder cancer survival","volume":"55","author":"Mungan","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.xcrm.2025.102255_bib31","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cell.2020.01.026","article-title":"Proteogenomic Characterization of Endometrial Carcinoma","volume":"180","author":"Dou","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102255_bib32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic Signaling Pathways in The Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102255_bib33","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1016\/j.cell.2023.07.013","article-title":"Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation","volume":"186","author":"Geffen","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102255_bib34","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-023-37568-9","article-title":"Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer","volume":"14","author":"Robertson","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102255_bib35","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.xcrm.2025.102255_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/srep10957","article-title":"Biological determinants of bladder cancer gene expression subtypes","volume":"5","author":"Aine","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2025.102255_bib37","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2023.05.037","article-title":"Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors","volume":"85","author":"Groeneveld","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.xcrm.2025.102255_bib38","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-022-01291-7","article-title":"Integrated proteogenomic characterization of urothelial carcinoma of the bladder","volume":"15","author":"Xu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102255_bib39","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1016\/j.cell.2024.05.039","article-title":"Pan-cancer proteogenomics expands the landscape of therapeutic targets","volume":"187","author":"Savage","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102255_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911747","article-title":"Monoamine Oxidase Inhibitors Prevent Glucose-Dependent Energy Production, Proliferation and Migration of Bladder Carcinoma Cells","volume":"23","author":"Resta","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2025.102255_bib41","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.18632\/oncotarget.27023","article-title":"Correction: Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38\/p53\/p21 and ATM signals","volume":"10","author":"Xie","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102255_bib42","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1158\/2326-6066.CIR-18-0619","article-title":"Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer","volume":"7","author":"Reddy","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2025.102255_bib43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2025.102255_bib44","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The Immune Landscape of Cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2025.102255_bib45","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1158\/0008-5472.CAN-18-2952","article-title":"Cancer-Associated Fibroblasts Produce Netrin-1 to Control Cancer Cell Plasticity","volume":"79","author":"Sung","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102255_bib46","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41586-023-06372-2","article-title":"Pharmacological targeting of netrin-1 inhibits EMT in cancer","volume":"620","author":"Lengrand","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102255_bib47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41586-023-06367-z","article-title":"Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer","volume":"620","author":"Cassier","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102255_bib48","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.xcrm.2025.102255_bib49","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/cas.13028","article-title":"Glycogen synthase kinase-3\u03b2 is a pivotal mediator of cancer invasion and resistance to therapy","volume":"107","author":"Domoto","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.xcrm.2025.102255_bib50","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1038\/s41467-018-07644-6","article-title":"GSK3 suppression upregulates \u03b2-catenin and c-Myc to abrogate KRas-dependent tumors","volume":"9","author":"Kazi","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102255_bib51","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1080\/02648725.2023.2199188","article-title":"PLC\u03b5 promotes the Warburg effect and tumorigenesis through AKT\/GSK3\u03b2\/Cdc25a in bladder cancer","volume":"40","author":"Fan","year":"2023","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"10.1016\/j.xcrm.2025.102255_bib52","first-page":"87","article-title":"Expression of tumoral GSK3-\u03b2, PD-L1, and CD8 cell density in urothelial carcinomas, association with tumor grade and overall survival","volume":"12","author":"Almeida Rodrigues","year":"2023","journal-title":"Am. J. Clin. Exp. Immunol."},{"key":"10.1016\/j.xcrm.2025.102255_bib53","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.15252\/embj.201487943","article-title":"Msp1\/ATAD1 maintains mitochondrial function by facilitating the degradation of mislocalized tail-anchored proteins","volume":"33","author":"Chen","year":"2014","journal-title":"EMBO J."},{"key":"10.1016\/j.xcrm.2025.102255_bib54","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1073\/pnas.1405755111","article-title":"The conserved AAA-ATPase Msp1 confers organelle specificity to tail-anchored proteins","volume":"111","author":"Okreglak","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102255_bib55","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.82860","article-title":"Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunction","volume":"11","author":"Winter","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.xcrm.2025.102255_bib56","doi-asserted-by":"crossref","first-page":"D1251","DOI":"10.1093\/nar\/gkv1003","article-title":"MitoCarta2.0: an updated inventory of mammalian mitochondrial proteins","volume":"44","author":"Calvo","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102255_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031297","article-title":"Mitochondrial Processing Peptidases-Structure, Function and the Role in Human Diseases","volume":"23","author":"Kunov\u00e1","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2025.102255_bib58","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1146\/annurev-biochem-062917-012739","article-title":"Mitochondrial Proteases: Multifaceted Regulators of Mitochondrial Plasticity","volume":"89","author":"Deshwal","year":"2020","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.xcrm.2025.102255_bib59","doi-asserted-by":"crossref","first-page":"D624","DOI":"10.1093\/nar\/gkx1134","article-title":"The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database","volume":"46","author":"Rawlings","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102255_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/cells7100163","article-title":"AAA Proteases: Guardians of Mitochondrial Function and Homeostasis","volume":"7","author":"Opali\u0144ska","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.xcrm.2025.102255_bib61","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1007\/s12035-023-03768-z","article-title":"Multifaceted Roles of AFG3L2, a Mitochondrial ATPase in Relation to Neurological Disorders","volume":"61","author":"Ghosh Dastidar","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.xcrm.2025.102255_bib62","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.18632\/oncotarget.23869","article-title":"Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment","volume":"9","author":"Zhang","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102255_bib63","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11010-018-3365-1","article-title":"Biglycan promotes the chemotherapy resistance of colon cancer by activating NF-\u03baB signal transduction","volume":"449","author":"Liu","year":"2018","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.xcrm.2025.102255_bib64","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102255_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133206","article-title":"Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin","volume":"13","author":"Deininger","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2025.102255_bib66","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102255_bib67","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1158\/1078-0432.CCR-21-1807","article-title":"Heterogeneity and Molecular Diversity in Bladder Cancers: Deconstructing the Activity of An Antibody-Drug Conjugate","volume":"27","author":"Teo","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102255_bib68","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.euo.2021.11.005","article-title":"TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells","volume":"5","author":"Chou","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102255_bib69","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling","volume":"1","author":"Corsello","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2025.102255_bib70","first-page":"30","article-title":"Re: Mutational Patterns in Chemotherapy Resistant Muscle-Invasive Bladder Cancer","volume":"202","author":"Chang","year":"2019","journal-title":"J. Urol."},{"key":"10.1016\/j.xcrm.2025.102255_bib71","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-18-1106","article-title":"Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer","volume":"25","author":"Seiler","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102255_bib72","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41417-022-00477-y","article-title":"The V-ATPases in cancer and cell death","volume":"29","author":"Chen","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.xcrm.2025.102255_bib73","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.21037\/atm-20-1102","article-title":"Development of a prognostic signature for bladder cancer based on immune-related genes","volume":"8","author":"Shi","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102255_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56461-4","article-title":"9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer","volume":"9","author":"Kuroki","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2025.102255_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100938","article-title":"Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms","volume":"68","author":"Li","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.xcrm.2025.102255_bib76","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1038\/s41598-022-09438-9","article-title":"Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time","volume":"12","author":"Xu","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2025.102255_bib77","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","article-title":"Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes","volume":"81","author":"Sj\u00f6dahl","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.xcrm.2025.102255_bib78","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41416-021-01628-y","article-title":"Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting","volume":"126","author":"Ikarashi","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102255_bib79","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102255_bib80","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102255_bib81","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: Still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2025.102255_bib82","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.molcel.2023.02.020","article-title":"Mitochondrial protein transport: Versatility of translocases and mechanisms","volume":"83","author":"Busch","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2025.102255_bib83","doi-asserted-by":"crossref","first-page":"a041323","DOI":"10.1101\/cshperspect.a041323","article-title":"The Breast Cancer Proteome and Precision Oncology","volume":"13","author":"Lei","year":"2023","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.xcrm.2025.102255_bib84","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.biocel.2014.07.020","article-title":"Soluble biglycan as a biomarker of inflammatory renal diseases","volume":"54","author":"Hsieh","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.xcrm.2025.102255_bib85","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s41467-021-21422-x","article-title":"KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation","volume":"12","author":"Tran","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102255_bib86","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147849","article-title":"RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics","volume":"131","author":"Bekele","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102255_bib87","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nsmb.2022","article-title":"ERK and PDE4 cooperate to induce RAF isoform switching in melanoma","volume":"18","author":"Marquette","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.xcrm.2025.102255_bib88","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41586-022-05575-3","article-title":"An atlas of substrate specificities for the human serine\/threonine kinome","volume":"613","author":"Johnson","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102255_bib89","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.molcel.2004.11.055","article-title":"Regulation of Raf-1 by Direct Feedback Phosphorylation","volume":"17","author":"Dougherty","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2025.102255_bib90","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody-drug conjugates: in search of partners of choice","volume":"9","author":"Fuentes-Antr\u00e1s","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xcrm.2025.102255_bib91","doi-asserted-by":"crossref","first-page":"714","DOI":"10.37349\/etat.2024.00243","article-title":"Antibody-drug conjugates combinations in cancer treatment","volume":"5","author":"Pretelli","year":"2024","journal-title":"Explor Target Antitumor Ther."},{"key":"10.1016\/j.xcrm.2025.102255_bib92","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102255_bib93","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102255_bib94","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.eururo.2021.03.014","article-title":"Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab","volume":"80","author":"Necchi","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.xcrm.2025.102255_bib95","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie 2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2025.102255_bib96","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/bioinformatics\/btp698","article-title":"Fast and accurate long-read alignment with Burrows-Wheeler transform","volume":"26","author":"Li","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102255_bib97","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13059-014-0571-3","article-title":"CIRI: an efficient and unbiased algorithm for de novo circular RNA identification","volume":"16","author":"Gao","year":"2015","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2025.102255_bib98","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2025.102255_bib99","doi-asserted-by":"crossref","first-page":"D956","DOI":"10.1093\/nar\/gkx1090","article-title":"LinkedOmics: analyzing multi-omics data within and across 32 cancer types","volume":"46","author":"Vasaikar","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102255_bib100","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res."},{"key":"10.1016\/j.xcrm.2025.102255_bib101","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1093\/bioinformatics\/btp394","article-title":"Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads","volume":"25","author":"Ye","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102255_bib102","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41467-017-02391-6","article-title":"Perturbation-response genes reveal signaling footprints in cancer gene expression","volume":"9","author":"Schubert","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102255_bib103","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2025.102255_bib104","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1109\/TPAMI.2012.240","article-title":"Automatic relevance determination in nonnegative matrix factorization with the \u03b2-divergence","volume":"35","author":"Tan","year":"2013","journal-title":"IEEE Trans. Pattern Anal. Mach. Intell."},{"key":"10.1016\/j.xcrm.2025.102255_bib105","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","article-title":"Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs","volume":"28","author":"Saunders","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102255_bib106","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2025.102255_bib107","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ng.3126","article-title":"Trans-ancestry mutational landscape of hepatocellular carcinoma genomes","volume":"46","author":"Totoki","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102255_bib108","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13059-015-0617-1","article-title":"CopywriteR: DNA copy number detection from off-target sequence data","volume":"16","author":"Kuilman","year":"2015","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2025.102255_bib109","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102255_bib110","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res."},{"key":"10.1016\/j.xcrm.2025.102255_bib111","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2025.102255_bib112","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1021\/acs.jproteome.0c00544","article-title":"Fast Deisotoping Algorithm and Its Implementation in the MSFragger Search Engine","volume":"20","author":"Teo","year":"2021","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.xcrm.2025.102255_bib113","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1038\/s41467-023-39828-0","article-title":"Detecting diagnostic features in MS\/MS spectra of post-translationally modified peptides","volume":"14","author":"Geiszler","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102255_bib114","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nmeth.4256","article-title":"MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics","volume":"14","author":"Kong","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2025.102255_bib115","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41592-020-0912-y","article-title":"Philosopher: a versatile toolkit for shotgun proteomics data analysis","volume":"17","author":"da Veiga Leprevost","year":"2020","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2025.102255_bib116","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.1038\/s41467-023-41558-2","article-title":"SEPepQuant enhances the detection of possible isoform regulations in shotgun proteomics","volume":"14","author":"Dou","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102255_bib117","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102255_bib118","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2025.102255_bib119","doi-asserted-by":"crossref","first-page":"D733","DOI":"10.1093\/nar\/gkv1189","article-title":"Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation","volume":"44","author":"O\u2019Leary","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102255_bib124","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1021\/acs.jproteome.8b00217","article-title":"Streamlined Tandem Mass Tag (SL-TMT) Protocol: An Efficient Strategy for Quantitative (Phospho)proteome Profiling Using Tandem Mass Tag-Synchronous Precursor Selection-MS3","volume":"17","author":"Navarrete-Perea","year":"2018","journal-title":"J Proteome Res."},{"key":"10.1016\/j.xcrm.2025.102255_bib120","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/bioinformatics\/btx129","article-title":"Quantifying circular RNA expression from RNA-seq data using model-based framework","volume":"33","author":"Li","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102255_bib121","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1186\/s12864-019-6041-2","article-title":"SigProfilerMatrixGenerator: a tool for visualizing and exploring patterns of small mutational events","volume":"20","author":"Bergstrom","year":"2019","journal-title":"BMC Genom."},{"key":"10.1016\/j.xcrm.2025.102255_bib122","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102255_bib123","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125003283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125003283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T21:40:54Z","timestamp":1762638054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125003283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":124,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2666379125003283"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102255","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102255"}}